Axis Pediaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.00 M
- Paid Up Capital ₹ 4.95 M
- Company Age 15 Year, 8 Months
- Last Filing with ROC 31 Mar 2011
- Open Charges ₹ 3.00 M
About Axis Pediaceuticals
Axis Pediaceuticals Limited (APL) is a Public Limited Indian Non-Government Company incorporated in India on 10 June 2009 and has a history of 15 years and eight months. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2011. It's a company limited by shares with an authorized capital of Rs 7.00 M and a paid-up capital of Rs 4.95 M.
The company currently has active open charges totaling ₹3.00 M.
Narasimhan Sitaram, Purushothaman Babu, Srinivasan Sellappa, and Four other members serve as directors at the Company.
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85110TN2009PLC071901
- Company No.
071901
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
10 Jun 2009
- Date of AGM
30 Sep 2011
- Date of Balance Sheet
31 Mar 2011
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Axis Pediaceuticals?
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narasimhan Sitaram  | Director | 10-Jun-2009 | Current |
| Purushothaman Babu | Director | 10-Jun-2009 | Current |
| Srinivasan Sellappa | Director | 10-Jun-2009 | Current |
| Nagarajan Thangarathinam | Director | 10-Jun-2009 | Current |
| Narasimhan Gopalan | Additional Director | 16-Mar-2011 | Current |
| Venkataraman Balaji | Additional Director | 16-Mar-2011 | Current |
Financial Performance of Axis Pediaceuticals.
Enhance accessibility to Axis Pediaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Axis Pediaceuticals?
Unlock access to Axis Pediaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Sep 2010 | Bank Of India | ₹3.00 M | Open |
How Many Employees Work at Axis Pediaceuticals?
Unlock and access historical data on people associated with Axis Pediaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Axis Pediaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Axis Pediaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
